Spots Global Cancer Trial Database for hematologic disorders
Every month we try and update this database with for hematologic disorders cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | NCT00636909 | AML ALL CML Chronic Pha... CLL MDS RELAPSED NON-HO... APLASTIC ANEMIA MULTIPLE MYELOM... MYELOPROLIFERAT... | Cyclophosphamid... fludarabine cyclosporine methotrexate G-CSF | - 65 Years | Beth Israel Deaconess Medical Center | |
| Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) | NCT02322320 | Multiple Myelom... | Lenalidomide | 18 Years - 70 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| MM CAR-T to Upgrade Response BMTCTN1902 | NCT05032820 | Multiple Myelom... | Lenalidomide an... | 18 Years - 71 Years | Medical College of Wisconsin | |
| Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents | NCT01737554 | Cancer Hematologic Dis... | Catheter Resist... | 5 Years - 24 Years | St. Jude Children's Research Hospital | |
| A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma | NCT01063907 | Multiple Myelom... | KW-2478 Bortezomib | 18 Years - | Kyowa Kirin Co., Ltd. | |
| Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents | NCT01737554 | Cancer Hematologic Dis... | Catheter Resist... | 5 Years - 24 Years | St. Jude Children's Research Hospital | |
| Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) | NCT01109004 | Multiple Myelom... | Lenalidomide lenalidomide, b... Lenalidomide | - 70 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) | NCT01109004 | Multiple Myelom... | Lenalidomide lenalidomide, b... Lenalidomide | - 70 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) | NCT01109004 | Multiple Myelom... | Lenalidomide lenalidomide, b... Lenalidomide | - 70 Years | National Heart, Lung, and Blood Institute (NHLBI) | |
| Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders | NCT02484053 | Hematologic Dis... Oncologic Disor... Rheumatologic D... | Rituximab | 1 Year - 19 Years | Baylor College of Medicine | |
| Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive Debriefing | NCT00909207 | Advanced Cancer... Hematologic Dis... Solid Tumors | Interview | 18 Years - | M.D. Anderson Cancer Center | |
| Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) | NCT02322320 | Multiple Myelom... | Lenalidomide | 18 Years - 70 Years | National Heart, Lung, and Blood Institute (NHLBI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
